SG11201408395WA - Substituted pyridine azolopyrimidine - 5 - (6h) - one compounds - Google Patents
Substituted pyridine azolopyrimidine - 5 - (6h) - one compoundsInfo
- Publication number
- SG11201408395WA SG11201408395WA SG11201408395WA SG11201408395WA SG11201408395WA SG 11201408395W A SG11201408395W A SG 11201408395WA SG 11201408395W A SG11201408395W A SG 11201408395WA SG 11201408395W A SG11201408395W A SG 11201408395WA SG 11201408395W A SG11201408395W A SG 11201408395WA
- Authority
- SG
- Singapore
- Prior art keywords
- lllll
- international
- llll
- compounds
- san diego
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- FWVSASLJILDCDH-UHFFFAOYSA-N N1C=NC=C2C1=CC=N2.N2=CC=CC=C2 Chemical class N1C=NC=C2C1=CC=N2.N2=CC=CC=C2 FWVSASLJILDCDH-UHFFFAOYSA-N 0.000 title abstract 2
- 102220240796 rs553605556 Human genes 0.000 abstract 2
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 150000005829 chemical entities Chemical class 0.000 abstract 1
- 230000007278 cognition impairment Effects 0.000 abstract 1
- 238000000375 direct analysis in real time Methods 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 238000012063 dual-affinity re-targeting Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261661091P | 2012-06-18 | 2012-06-18 | |
PCT/US2013/046415 WO2013192229A1 (en) | 2012-06-18 | 2013-06-18 | Substituted pyridine azolopyrimidine - 5 - (6h) - one compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201408395WA true SG11201408395WA (en) | 2015-01-29 |
Family
ID=49756458
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201408397SA SG11201408397SA (en) | 2012-06-18 | 2013-06-18 | Substituted thiophene- and furan-fused azolopyrimidine-5-(6h)-one compounds |
SG10201703253XA SG10201703253XA (en) | 2012-06-18 | 2013-06-18 | Substituted pyridine azolopyrimidine-5-(6h)-one compounds |
SG11201408395WA SG11201408395WA (en) | 2012-06-18 | 2013-06-18 | Substituted pyridine azolopyrimidine - 5 - (6h) - one compounds |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201408397SA SG11201408397SA (en) | 2012-06-18 | 2013-06-18 | Substituted thiophene- and furan-fused azolopyrimidine-5-(6h)-one compounds |
SG10201703253XA SG10201703253XA (en) | 2012-06-18 | 2013-06-18 | Substituted pyridine azolopyrimidine-5-(6h)-one compounds |
Country Status (18)
Country | Link |
---|---|
US (7) | US9175010B2 (zh) |
EP (3) | EP2861603B1 (zh) |
JP (2) | JP6240180B2 (zh) |
KR (2) | KR102087756B1 (zh) |
CN (2) | CN104583217B (zh) |
AU (3) | AU2013277298B2 (zh) |
BR (2) | BR112014031731B1 (zh) |
CA (2) | CA2877149C (zh) |
DK (2) | DK2861603T3 (zh) |
ES (2) | ES2715325T3 (zh) |
HK (2) | HK1208023A1 (zh) |
IL (2) | IL236232A (zh) |
IN (2) | IN2015DN00334A (zh) |
MX (2) | MX357320B (zh) |
NZ (2) | NZ703950A (zh) |
RU (2) | RU2659779C2 (zh) |
SG (3) | SG11201408397SA (zh) |
WO (2) | WO2013192225A1 (zh) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2001284792A1 (en) * | 2000-08-10 | 2002-02-25 | Cold Spring Harbor Laboratory | Augmented cognitive training |
AU2013277298B2 (en) | 2012-06-18 | 2017-09-07 | Dart Neuroscience (Cayman) Ltd | Substituted pyridine azolopyrimidine - 5 - (6h) - one compounds |
JP6396229B2 (ja) * | 2014-01-27 | 2018-09-26 | 株式会社ポーラファルマ | 使用時泡状を呈する外用医薬組成物 |
JP6396230B2 (ja) * | 2014-01-27 | 2018-09-26 | 株式会社ポーラファルマ | 使用時泡状を呈する外用医薬組成物 |
JP6396231B2 (ja) * | 2014-01-27 | 2018-09-26 | 株式会社ポーラファルマ | 使用時泡状を呈する外用医薬組成物 |
GB201406486D0 (en) * | 2014-04-10 | 2014-05-28 | Redx Pharma Ltd | Antibacterial compounds |
TW201629064A (zh) | 2014-10-10 | 2016-08-16 | H 朗德貝克公司 | 作爲pde1抑制劑之三唑並吡酮 |
JO3627B1 (ar) | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
WO2017046603A1 (en) * | 2015-09-18 | 2017-03-23 | Redx Pharma Plc | Antibacterial compounds and new uses thereof |
TWI609870B (zh) | 2016-02-12 | 2018-01-01 | 美國禮來大藥廠 | Pde1抑制劑 |
TWI729109B (zh) | 2016-04-12 | 2021-06-01 | 丹麥商H 朗德貝克公司 | 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮 |
JOP20170164A1 (ar) * | 2016-08-25 | 2019-01-30 | Lilly Co Eli | مشتق ترايازولو بيرازينون مفيد كمثبط لـ pde1 بشري |
JP7112413B2 (ja) * | 2016-10-18 | 2022-08-03 | ハー・ルンドベック・アクチエゼルスカベット | Pde1阻害剤としてのイミダゾピラジノン、ピラゾロピリミジノンおよびピラゾロピリジノン |
KR20190077349A (ko) | 2016-10-28 | 2019-07-03 | 하. 룬드벡 아크티에셀스카브 | 이미다조피라지논의 투여를 포함하는 병용 치료 |
WO2018078038A1 (en) | 2016-10-28 | 2018-05-03 | H. Lundbeck A/S | Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders |
US10981916B2 (en) | 2016-12-28 | 2021-04-20 | Dart Neuroscience, Llc | Substituted pyrazolopyrimidinone compounds as PDE2 inhibitors |
CN110392686A (zh) * | 2016-12-30 | 2019-10-29 | 频率治疗公司 | 1h-吡咯-2,5-二酮化合物以及使用它们来诱导干/祖支持细胞自我更新的方法 |
KR102643197B1 (ko) * | 2017-02-23 | 2024-03-06 | 베링거 인겔하임 인터내셔날 게엠베하 | 화합물 iii의 새로운 의학 용도 |
AR112457A1 (es) | 2017-08-02 | 2019-10-30 | Lilly Co Eli | Derivados de [1,2,4]triazolo[4,3-a]pirazin-6(5h)-ona |
AR112346A1 (es) * | 2017-08-10 | 2019-10-16 | Lilly Co Eli | Derivados de [1,2,4]triazolo |
US11434247B1 (en) | 2017-11-27 | 2022-09-06 | Dart Neuroscience Llc | Substituted furanopyrimidine compounds as PDE1 inhibitors |
GB2575490A (en) * | 2018-07-12 | 2020-01-15 | Recordati Ind Chimica E Farmaceutica Spa | P2X3 receptor antagonists |
JP2022545802A (ja) * | 2019-08-22 | 2022-10-31 | イントラ-セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
CN112778311B (zh) * | 2019-11-01 | 2024-06-04 | 上海翰森生物医药科技有限公司 | 含氮并环类衍生物抑制剂、其制备方法和应用 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3046366A1 (de) * | 1980-12-09 | 1982-07-08 | Bayer Ag, 5090 Leverkusen | Tricyclische cytosinderivate zur verwendung in arzneimitteln und verfahren zu ihrer herstellung |
DE3146599A1 (de) | 1981-11-25 | 1983-07-07 | Basf Ag, 6700 Ludwigshafen | Neue triazolochinazoline, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen |
EP0181282A1 (de) | 1984-10-01 | 1986-05-14 | Ciba-Geigy Ag | Triazolochinazolinverbindungen |
JPS62135475A (ja) * | 1985-09-30 | 1987-06-18 | チバ−ガイギ− アクチエンゲゼルシヤフト | 2−置換−e−融合−〔1,2,4〕トリアゾロ−〔1,5−C〕ピリミジン |
DE3677445D1 (de) * | 1985-09-30 | 1991-03-14 | Ciba Geigy Ag | 2-substituierte-e-kondensierte(1,5-c)-pyrimidine, pharmazeutische zubereitungen und ihre verwendung. |
US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
FR2659329B1 (fr) | 1990-03-09 | 1994-06-03 | Adir | Nouveaux derives d'imidazo [1,2-c] quinazoline, leur procede de preparation et les compositions pharmaceutiques les renfermant. |
WO1999038504A1 (en) * | 1998-01-29 | 1999-08-05 | Sepracor Inc. | Pharmaceutical uses of optically pure (-)-bupropion |
ES2166270B1 (es) | 1999-07-27 | 2003-04-01 | Almirall Prodesfarma Sa | Derivados de 8-fenil-6,9-dihidro-(1,2,4,)triazolo(3,4-i)purin-5-ona. |
DE10012373A1 (de) * | 2000-03-14 | 2001-09-20 | Dresden Arzneimittel | Verwendung von Pyrido[3,2-e]-pyrazinonen als Inhibitoren der Phosphodiesterase 5 zur Therapie von erektiler Dysfunktion |
AU2001284792A1 (en) | 2000-08-10 | 2002-02-25 | Cold Spring Harbor Laboratory | Augmented cognitive training |
US7868015B2 (en) | 2000-08-10 | 2011-01-11 | Cold Spring Harbor Laboratory | Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit |
US8153646B2 (en) | 2000-08-10 | 2012-04-10 | Dart Neuroscience (Cayman) Ltd. | Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation |
FR2897061B1 (fr) * | 2006-02-03 | 2010-09-03 | Sanofi Aventis | Derives de n-heteroaryl-carboxamides tricycliques contenant un motif benzimidazole, leur preparation et leur application en therapeutique. |
KR20090042227A (ko) * | 2006-06-06 | 2009-04-29 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 유기 화합물 |
EP2139333A4 (en) * | 2007-03-28 | 2010-11-10 | Merck Sharp & Dohme | SUBSTITUTED PYRIDO [3,2-E] [1,2,4] TRIAZOLO [4,3-C] PYRIMIDINE DERIVATIVES AS MODULATORS OF THE CANNABINOID-1 RECEPTOR |
WO2008144455A1 (en) | 2007-05-15 | 2008-11-27 | Helicon Therapeutics, Inc. | Methods of identifying genes involved in memory formation using small interfering rna(sirna) |
CN101809142A (zh) * | 2007-09-26 | 2010-08-18 | 通用电气医疗集团生物科学生物方法公司 | 三维可用后即弃生物反应器 |
WO2009075784A1 (en) | 2007-12-06 | 2009-06-18 | Intra-Cellular Therapies, Inc. | Organic compounds |
JP2011507910A (ja) | 2007-12-21 | 2011-03-10 | ユニバーシティー オブ ロチェスター | 真核生物の寿命を変更するための方法 |
CN102223799A (zh) * | 2008-12-06 | 2011-10-19 | 细胞内治疗公司 | 有机化合物 |
BRPI0922348A2 (pt) | 2008-12-06 | 2015-08-11 | Intracellular Therapies Inc | Compostos orgânicos |
WO2010098839A1 (en) | 2009-02-25 | 2010-09-02 | Intra-Cellular Therapies, Inc. | Pde 1 inhibitors for ophthalmic disorders |
EP2434895A4 (en) | 2009-05-13 | 2013-08-07 | Intra Cellular Therapies Inc | ORGANIC CONNECTIONS |
WO2011153136A1 (en) | 2010-05-31 | 2011-12-08 | Intra-Cellular Therapies, Inc. | Organic compounds |
TW201206937A (en) | 2010-05-31 | 2012-02-16 | Intra Cellular Therapies Inc | Organic compounds |
JP5911854B2 (ja) | 2010-05-31 | 2016-04-27 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 有機化合物 |
EP2590657A4 (en) | 2010-05-31 | 2014-02-12 | Intra Cellular Therapies Inc | ORGANIC COMPOUNDS |
EP2717877B1 (en) | 2011-06-10 | 2017-11-08 | Intra-Cellular Therapies, Inc. | Organic compounds |
AU2013277298B2 (en) | 2012-06-18 | 2017-09-07 | Dart Neuroscience (Cayman) Ltd | Substituted pyridine azolopyrimidine - 5 - (6h) - one compounds |
-
2013
- 2013-06-18 AU AU2013277298A patent/AU2013277298B2/en active Active
- 2013-06-18 EP EP13807565.0A patent/EP2861603B1/en active Active
- 2013-06-18 ES ES13807565T patent/ES2715325T3/es active Active
- 2013-06-18 WO PCT/US2013/046403 patent/WO2013192225A1/en active Application Filing
- 2013-06-18 DK DK13807565.0T patent/DK2861603T3/en active
- 2013-06-18 RU RU2015100209A patent/RU2659779C2/ru active
- 2013-06-18 SG SG11201408397SA patent/SG11201408397SA/en unknown
- 2013-06-18 CA CA2877149A patent/CA2877149C/en active Active
- 2013-06-18 SG SG10201703253XA patent/SG10201703253XA/en unknown
- 2013-06-18 WO PCT/US2013/046415 patent/WO2013192229A1/en active Application Filing
- 2013-06-18 ES ES18213541T patent/ES2904267T3/es active Active
- 2013-06-18 IN IN334DEN2015 patent/IN2015DN00334A/en unknown
- 2013-06-18 US US13/920,974 patent/US9175010B2/en active Active
- 2013-06-18 US US14/408,942 patent/US9284335B2/en active Active
- 2013-06-18 EP EP13807708.6A patent/EP2861605B1/en active Active
- 2013-06-18 DK DK18213541.8T patent/DK3489238T3/da active
- 2013-06-18 AU AU2013277294A patent/AU2013277294C1/en active Active
- 2013-06-18 CN CN201380043254.5A patent/CN104583217B/zh active Active
- 2013-06-18 IN IN335DEN2015 patent/IN2015DN00335A/en unknown
- 2013-06-18 CN CN201380043291.6A patent/CN104583213B/zh active Active
- 2013-06-18 JP JP2015518522A patent/JP6240180B2/ja active Active
- 2013-06-18 MX MX2014015740A patent/MX357320B/es active IP Right Grant
- 2013-06-18 CA CA2877146A patent/CA2877146C/en active Active
- 2013-06-18 KR KR1020157001117A patent/KR102087756B1/ko active IP Right Grant
- 2013-06-18 MX MX2014015737A patent/MX359615B/es active IP Right Grant
- 2013-06-18 SG SG11201408395WA patent/SG11201408395WA/en unknown
- 2013-06-18 NZ NZ703950A patent/NZ703950A/en unknown
- 2013-06-18 BR BR112014031731-3A patent/BR112014031731B1/pt active IP Right Grant
- 2013-06-18 EP EP18213541.8A patent/EP3489238B8/en active Active
- 2013-06-18 BR BR112014031730-5A patent/BR112014031730B1/pt active IP Right Grant
- 2013-06-18 RU RU2015100213A patent/RU2653054C2/ru active
- 2013-06-18 JP JP2015518523A patent/JP6129960B2/ja active Active
- 2013-06-18 NZ NZ703949A patent/NZ703949A/en unknown
- 2013-06-18 US US14/408,927 patent/US9499562B2/en active Active
- 2013-06-18 KR KR1020157001198A patent/KR102191816B1/ko active IP Right Grant
-
2014
- 2014-12-14 IL IL236232A patent/IL236232A/en active IP Right Grant
- 2014-12-14 IL IL236233A patent/IL236233A/en active IP Right Grant
-
2015
- 2015-09-02 HK HK15108586.6A patent/HK1208023A1/zh unknown
- 2015-09-02 HK HK15108624.0A patent/HK1208024A1/zh unknown
- 2015-09-14 US US14/853,856 patent/US9533996B2/en active Active
-
2016
- 2016-11-17 US US15/354,804 patent/US10092575B2/en active Active
- 2016-12-29 US US15/394,058 patent/US10105367B2/en active Active
-
2017
- 2017-12-07 AU AU2017272245A patent/AU2017272245B2/en active Active
-
2018
- 2018-10-18 US US16/164,726 patent/US10376514B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201408395WA (en) | Substituted pyridine azolopyrimidine - 5 - (6h) - one compounds | |
SG11201810983PA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
SG11201806302RA (en) | Inhibitors of receptor-interacting protein kinase 1 | |
SG11201806861SA (en) | Combination therapy with anti-cd73 antibodies | |
SG11201903331QA (en) | Restimulation of cryopreserved tumor infiltrating lymphocytes | |
SG11201807252QA (en) | Anti-lag-3 antibodies | |
SG11201809714TA (en) | Piperidines as menin inhibitors | |
SG11201809559UA (en) | Substituted pyridines as inhibitors of dnmt1 | |
SG11201808878UA (en) | Heterocyclic compounds as ret kinase inhibitors | |
SG11201407682TA (en) | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | |
SG11201408750VA (en) | NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS | |
SG11201908179UA (en) | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | |
SG11201407784UA (en) | Engineered botulinum neurotoxin | |
SG11201407900WA (en) | Benzo [c] isoxazoloazepine bromodomain inhibitors and uses thereof | |
SG11201500005SA (en) | Pyrimidine pyrazolyl derivatives | |
SG11201407220YA (en) | N-alkyltriazole compounds as lpar antagonists | |
SG11201407372UA (en) | Nampt inhibitors | |
SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
SG11201408279QA (en) | Social sharing of security information in a group | |
SG11201407669QA (en) | Methods for improving safety of blood-brain barrier transport | |
SG11201804668UA (en) | Bicyclic inhibitors of pad4 | |
SG11201408780XA (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
SG11201408232RA (en) | 1,2,4-triazine-6-carboxamide kinase inhibitors | |
SG11201407037UA (en) | Catechol o-methyltransferase activity inhibiting compounds |